| Filed | Form | Description | |
|---|---|---|---|
| 8/28/25 | DEFA14A | ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS | → |
| 7/30/25 | DEFA14A | ADDITIONAL DEFINITIVE PROXY MATERIALS | → |
| 7/30/25 | DEF 14A | DEFINITIVE PROXY | → |
| 5/8/24 | DEFA14A | FORM DEFA14A | → |
| 5/8/24 | DEF 14A | DEFINITIVE PROXY STATEMENT | → |
| 4/22/24 | PRE 14A | PRELIMINARY PROXY STATEMENT | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 2/6/26 | 4 | 4 | → |
| 2/6/26 | 4 | 4 | → |
| 2/6/26 | 4 | 4 | → |
| 2/6/26 | 4 | 4 | → |
| 2/6/26 | 4 | 4 | → |
| 2/6/26 | 4 | 4 | → |
| ↓ | |||
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.